Targeted therapy of colorectal cancer
- VernacularTitle:大肠癌的靶向治疗
- Author:
Zhaoyan WANG
;
Erbing WANG
- Publication Type:Journal Article
- Keywords:
Bevacizumab;
Cetuximab;
Colorectal cancer
- From:
Cancer Research and Clinic
2001;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
This article reviews the role of bevacizumab (BV) and cetuximab (C225) in the treatment of the patients with advanced or metastatic colorectal cancer(CRC). The molecules targeting agents BV and C225 are being specifically blocking biological response of VEGF and EGFR. The clinical application of these agents for CRC is effective and well tolerated. Unlike traditional chemotherapy, it primarily inhibits tumor growth rather than regression. The combination of targeted agents (BV and C225) with cytotoxic agents holds the promise of enhanced chemotherapy benefits, prolonged survival and improved quality of life for patients with CRC
